← All trials
NCT05923918
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2023
- Primary completion
- May 31, 2024
- Completion date
- Jun 30, 2024
- First posted
- Jun 28, 2023
- Last posted
- Jun 28, 2023
- Enrollment
- 246
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Pharmbio KoreaLead sponsor
- University of UlsanOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.